Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster

Akifumi Kanai, Satoru Osawa, Asaha Suzuki, Rie Ishimaru, Sumio Hoka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. Postherpetic neuralgia (PHN) is one of the most painful neuropathic conditions, the mechanism of which remains unclear. There is no universally accepted treatment. The pain in PHN is often relieved by bathing, heating, or sympathetic blockade, suggesting a circulation-dependent property of the pain. Therefore, we examined the effectiveness of prostaglandin E1 (PGE1), which has an analgesic effect via improvement of peripheral blood circulation, for patients with PHN. Design. A total of 27 patients with PHN underwent intravenous administration of 60 μg of PGE1 dissolved in 100 mL of physiological saline and 5 mL of 8.4% sodium bicarbonate solution at an infusion rate of 0.02 μg/kg/min. Oral administration of PGE1, limaprost alfadex, was followed at doses of 30 μg/day for 2 weeks. Pain at rest and tactile allodynia before and after the treatment was evaluated with visual analog scale (VAS). Results. Intravenous PGE1 significantly decreased VAS in rest pain and tactile allodynia without severe adverse effects. The analgesic effect of PGE1 continued during the 2 weeks of oral administration of PGE1. Oral PGE1 caused nausea in seven cases, diarrhea in three, and abdominal distention in one subject. All subjects, except for two cases of nausea, continued the treatment until the end of the study, although some required a decrease in the dose to 15 μg/day. During the 2-week oral administration, the VAS did not change remarkably in the three patients whose VAS were not decreased by at least 80% during the initial infusion. Conclusions. The results of the present study indicate that oral PGE1 following the intravenous administration produces prompt and continuous analgesia in patients with PHN. Moreover, the intravenous treatment using PGE1 appears useful for predicting the analgesic effect of PGE1 in the patients.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalPain Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

Fingerprint

Alprostadil
Herpes Zoster
Neuralgia
Postherpetic Neuralgia
Visual Analog Scale
Oral Administration
Analgesics
Therapeutics
Pain
Hyperalgesia
Intravenous Administration
Nausea
Sodium Bicarbonate
Blood Circulation
Analgesia
Heating
Diarrhea

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. / Kanai, Akifumi; Osawa, Satoru; Suzuki, Asaha; Ishimaru, Rie; Hoka, Sumio.

In: Pain Medicine, Vol. 8, No. 1, 01.01.2007, p. 36-40.

Research output: Contribution to journalArticle

Kanai, Akifumi ; Osawa, Satoru ; Suzuki, Asaha ; Ishimaru, Rie ; Hoka, Sumio. / Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. In: Pain Medicine. 2007 ; Vol. 8, No. 1. pp. 36-40.
@article{d9344c86db254574907178271ef7ef43,
title = "Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster",
abstract = "Objective. Postherpetic neuralgia (PHN) is one of the most painful neuropathic conditions, the mechanism of which remains unclear. There is no universally accepted treatment. The pain in PHN is often relieved by bathing, heating, or sympathetic blockade, suggesting a circulation-dependent property of the pain. Therefore, we examined the effectiveness of prostaglandin E1 (PGE1), which has an analgesic effect via improvement of peripheral blood circulation, for patients with PHN. Design. A total of 27 patients with PHN underwent intravenous administration of 60 μg of PGE1 dissolved in 100 mL of physiological saline and 5 mL of 8.4{\%} sodium bicarbonate solution at an infusion rate of 0.02 μg/kg/min. Oral administration of PGE1, limaprost alfadex, was followed at doses of 30 μg/day for 2 weeks. Pain at rest and tactile allodynia before and after the treatment was evaluated with visual analog scale (VAS). Results. Intravenous PGE1 significantly decreased VAS in rest pain and tactile allodynia without severe adverse effects. The analgesic effect of PGE1 continued during the 2 weeks of oral administration of PGE1. Oral PGE1 caused nausea in seven cases, diarrhea in three, and abdominal distention in one subject. All subjects, except for two cases of nausea, continued the treatment until the end of the study, although some required a decrease in the dose to 15 μg/day. During the 2-week oral administration, the VAS did not change remarkably in the three patients whose VAS were not decreased by at least 80{\%} during the initial infusion. Conclusions. The results of the present study indicate that oral PGE1 following the intravenous administration produces prompt and continuous analgesia in patients with PHN. Moreover, the intravenous treatment using PGE1 appears useful for predicting the analgesic effect of PGE1 in the patients.",
author = "Akifumi Kanai and Satoru Osawa and Asaha Suzuki and Rie Ishimaru and Sumio Hoka",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1526-4637.2007.00249.x",
language = "English",
volume = "8",
pages = "36--40",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster

AU - Kanai, Akifumi

AU - Osawa, Satoru

AU - Suzuki, Asaha

AU - Ishimaru, Rie

AU - Hoka, Sumio

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Objective. Postherpetic neuralgia (PHN) is one of the most painful neuropathic conditions, the mechanism of which remains unclear. There is no universally accepted treatment. The pain in PHN is often relieved by bathing, heating, or sympathetic blockade, suggesting a circulation-dependent property of the pain. Therefore, we examined the effectiveness of prostaglandin E1 (PGE1), which has an analgesic effect via improvement of peripheral blood circulation, for patients with PHN. Design. A total of 27 patients with PHN underwent intravenous administration of 60 μg of PGE1 dissolved in 100 mL of physiological saline and 5 mL of 8.4% sodium bicarbonate solution at an infusion rate of 0.02 μg/kg/min. Oral administration of PGE1, limaprost alfadex, was followed at doses of 30 μg/day for 2 weeks. Pain at rest and tactile allodynia before and after the treatment was evaluated with visual analog scale (VAS). Results. Intravenous PGE1 significantly decreased VAS in rest pain and tactile allodynia without severe adverse effects. The analgesic effect of PGE1 continued during the 2 weeks of oral administration of PGE1. Oral PGE1 caused nausea in seven cases, diarrhea in three, and abdominal distention in one subject. All subjects, except for two cases of nausea, continued the treatment until the end of the study, although some required a decrease in the dose to 15 μg/day. During the 2-week oral administration, the VAS did not change remarkably in the three patients whose VAS were not decreased by at least 80% during the initial infusion. Conclusions. The results of the present study indicate that oral PGE1 following the intravenous administration produces prompt and continuous analgesia in patients with PHN. Moreover, the intravenous treatment using PGE1 appears useful for predicting the analgesic effect of PGE1 in the patients.

AB - Objective. Postherpetic neuralgia (PHN) is one of the most painful neuropathic conditions, the mechanism of which remains unclear. There is no universally accepted treatment. The pain in PHN is often relieved by bathing, heating, or sympathetic blockade, suggesting a circulation-dependent property of the pain. Therefore, we examined the effectiveness of prostaglandin E1 (PGE1), which has an analgesic effect via improvement of peripheral blood circulation, for patients with PHN. Design. A total of 27 patients with PHN underwent intravenous administration of 60 μg of PGE1 dissolved in 100 mL of physiological saline and 5 mL of 8.4% sodium bicarbonate solution at an infusion rate of 0.02 μg/kg/min. Oral administration of PGE1, limaprost alfadex, was followed at doses of 30 μg/day for 2 weeks. Pain at rest and tactile allodynia before and after the treatment was evaluated with visual analog scale (VAS). Results. Intravenous PGE1 significantly decreased VAS in rest pain and tactile allodynia without severe adverse effects. The analgesic effect of PGE1 continued during the 2 weeks of oral administration of PGE1. Oral PGE1 caused nausea in seven cases, diarrhea in three, and abdominal distention in one subject. All subjects, except for two cases of nausea, continued the treatment until the end of the study, although some required a decrease in the dose to 15 μg/day. During the 2-week oral administration, the VAS did not change remarkably in the three patients whose VAS were not decreased by at least 80% during the initial infusion. Conclusions. The results of the present study indicate that oral PGE1 following the intravenous administration produces prompt and continuous analgesia in patients with PHN. Moreover, the intravenous treatment using PGE1 appears useful for predicting the analgesic effect of PGE1 in the patients.

UR - http://www.scopus.com/inward/record.url?scp=33846346228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846346228&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2007.00249.x

DO - 10.1111/j.1526-4637.2007.00249.x

M3 - Article

C2 - 17244102

AN - SCOPUS:33846346228

VL - 8

SP - 36

EP - 40

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 1

ER -